Sigyn Therapeutics, Inc.

Equities

SIGY

US82674U2050

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets Other stock markets 12:27:32 2024-05-15 EDT			5-day change	1st Jan Change
5.25 ^USD	+5.00%		-.--%	+10.99%

05-14	Sigyn Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02-20	Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Sigyn Therapeutics, Inc. Appoints Ajay Verma, M.D., Ph.D. to its Scientific Advisory Board

March 31, 2022 at 08:30 am

Sigyn Therapeutics, Inc. announced the appointment of Ajay Verma, M.D., Ph.D.to its Scientific Advisory Board. Dr. Verma is a neurologist, neuroscientist, drug developer, inventor, and biotech science advisor. Dr. Verma most recently headed R&D efforts at Yumanity Therapeutics, developing drugs against novel targets for treating neurodegenerative diseases.

Prior to that he was the EVP of Research and Experimental Medicine at Codiak Biosciences.

Latest news about Sigyn Therapeutics, Inc.

Sigyn Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-20	CI
Sigyn Therapeutics, Inc. Appoints Jerry Deciccio as Chief Financial Officer	12-12	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Sigyn Therapeutics, Inc. Discloses "DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES" Patent Submission and Related ImmunePrep Trademark Application	23-05-17	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Sigyn Therapeutics, Inc. Announces Appointment of Annette Marleau as Chief Scientific Officer	23-04-11	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Sigyn Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Sigyn Therapeutics, Inc. Announces Cancer-Related Patent Submission	22-10-06	CI
Sigyn Therapeutics, Inc. Announces Board Changes, Effective October 10, 2022	22-10-04	CI
Sigyn Therapeutics Announces First-In-Human Clinical Strategy to Address Inflammation and Endotoxemia in End-Stage Renal Disease Patients	22-09-14	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Sigyn Therapeutics, Inc. has filed an IPO in the amount of $9.2 million.	22-06-22	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Sigyn Therapeutics Appoints Donald J. Hillebrand, M.D. to its Scientific Advisory Board	22-04-26	CI
Sigyn Therapeutics, Inc. Appoints Ajay Verma, M.D., Ph.D. to its Scientific Advisory Board	22-03-31	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-21	CI
Sigyn Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	22-03-20	CI
Sigyn Therapeutics, Inc. Appoints H. David Humes, MD to Its Scientific Advisory Board	22-03-15	CI
Sigyn Therapeutics, Inc. Appoints Alexander S. Yevzlin to its Scientific Advisory Board	22-03-09	CI
Sigyn Therapeutics, Inc. Appoints Jeremy Ferrell as Chief Financial Officer, Effective March 9, 2022	22-03-02	CI
Sigyn Therapeutics Announces Completion of Animal Studies	22-02-23	CI

Chart Sigyn Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Sigyn Therapeutics, Inc. (Sigyn) is a development-stage company. The Company is focused on creating therapeutic solutions that address unmet needs in global health. The Company's product candidate, Sigyn Therapy, is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders. Its treatment indications include endotoxemia and inflammation in end-stage renal disease (dialysis) patients, sepsis (a cause of hospital deaths), community-acquired pneumonia (a cause of death among infectious diseases), and emerging pandemic threats. Sigyn Therapy is a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy (CRRT) machines. The Companyâs development pipeline includes a cancer treatment system comprised of ChemoPrep to enhance the tumor site delivery of chemotherapy, and ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
SIGYN THERAPEUTICS, INC.	+10.99%	6.61M
ABBOTT LABORATORIES	-5.60%	181B
MEDTRONIC PLC	-4.45%	101B
BECTON, DICKINSON AND COMPANY	-4.15%	67.54B
DEXCOM, INC.	-8.63%	45.09B
CENCORA, INC.	+9.70%	44.37B
HOYA CORPORATION	+6.13%	40.7B
METTLER-TOLEDO INTERNATIONAL, INC.	+15.22%	29.85B
TERUMO CORPORATION	+14.80%	24.49B
WEST PHARMACEUTICAL SERVICES, INC.	-6.46%	23.99B

Other Medical Equipment, Supplies & Distribution